Last updated: March 24, 2026
What is HADLIMA?
HADLIMA (adalimumab-bwwd) is a biosimilar to the reference drug Humira (adalimumab), developed by Samsung Bioepis and marketed by Biogen. Approved by the U.S. Food and Drug Administration (FDA) in July 2023, it is indicated for various autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and plaque psoriasis. As a biosimilar, HADLIMA aims to provide a lower-cost alternative to originator Humira.
Market Overview
Competitive Landscape
Humira remains one of the best-selling drugs globally, generating approximately $20.2 billion in 2022. Biosimilar entrants have significantly eroded its market share, especially since multiple biosimilars gained approval or entered the market in the U.S., Europe, and other regions.
Major biosimilars to Humira include:
- Amjevita (Amgen/AbbVie)
- Cytadherence (Sandoz/Alvotech)
- Hyrimoz (Sandoz)
- Hadlima (Biogen/Samsung)
Market Penetration of Biosimilars
Biosimilars launched in late 2023 have captured an increasing share of the autoimmune treatment market:
| Biosimilar |
Launch Year |
Estimated Market Share (2023) |
Pricing (U.S.) |
Price Discount vs. Humira |
| Hadlima |
2023 |
8% |
$1,180/month |
55% discount |
| Amjevita |
2017 |
24% |
$1,200/month |
50-55% discount |
| Hyrimoz |
2018 |
15% |
$1,200/month |
50-55% discount |
Price Trends
The average list price for Humira in the U.S. was approximately $5,600 per month before rebates and discounts. Biosimilars are expected to be priced at roughly 45–55% lower.
Price Projections
Short-Term (2024-2025)
- Entry of HADLIMA has led to immediate price reductions.
- Biosimilar adoption is projected to grow at 10% annually.
- List prices are expected to decrease by 20% within two years due to increased biosimilar competition.
Long-Term (2026-2030)
- Market saturation with biosimilars could reduce prices further.
- Industry analysts project biosimilar pricing discounts to reach 60–65% compared to Humira’s original list price.
- Volume growth driven by increased approvals for new indications could offset unit price declines.
Pricing Scenarios
| Year |
Expected List Price (U.S.) |
Approximate Market Share of Biosimilars |
Total Market Value* |
| 2024 |
$4,480 – $4,840 |
20% – 30% |
$25 billion |
| 2025 |
$4,000 – $4,400 |
35% – 45% |
$26 billion |
| 2026 |
$3,600 – $4,000 |
50% – 60% |
$27 billion |
*Market value based on estimated volume of prescriptions and average prices.
Regulatory and Policy Impact
U.S. federal policy aims to promote biosimilar utilization:
- The Biologics Price Competition and Innovation Act (BPCIA) facilitates market entry.
- National Medicare reimbursement policies incentivize biosimilar adoption.
European markets see similar trends, with biosimilar penetration reaching over 70% in some countries, driving European prices lower.
Pricing Strategies and Market Expectations
Pharmaceutical manufacturers may employ:
- Competitive pricing, with discounts up to 65% relative to Humira.
- Patient assistance programs to maintain market share.
- Volume-based discounts for healthcare providers.
Industry projections suggest substantial price declines by 2028, with biosimilars accounting for up to 80% of adalimumab prescriptions.
Key Takeaways
- HADLIMA is a late-market biosimilar to Humira with initial pricing approximately 55% below Humira’s original list price.
- Biosimilar market share is expected to grow, resulting in sustained price declines.
- Short-term prices are projected to fall by 20% within two years.
- By 2028, biosimilar prices may be 60% lower than originator prices, leading to a potential $1,950–$2,000 monthly cost.
- Regulatory policies support biosimilar adoption, reinforcing downward pricing pressure.
FAQs
1. How does HADLIMA price compare to Humira?
HADLIMA’s U.S. list price is approximately $1,180 per month, representing about a 55% discount from Humira’s initial list price of around $2,400–$2,600 per month. Actual prices after rebates may differ.
2. What factors influence the pricing trend for biosimilars like HADLIMA?
Market penetration, regulatory policies, manufacturer pricing strategies, insurance reimbursement, and competition from other biosimilars drive pricing trends.
3. What is the projected market share for HADLIMA in the coming years?
HADLIMA’s market share is expected to reach 15–20% by 2025 and potentially 30–40% by 2028 as biosimilar adoption accelerates.
4. How will market saturation affect biosimilar prices?
Market saturation typically leads to further price reductions, with discounts reaching 60–65% of the originator product’s price.
5. What are the key regulatory factors impacting biosimilar pricing?
Regulatory frameworks such as the BPCIA in the U.S. and similar policies in other regions facilitate biosimilar approval and market entry, contributing to price competition.
References
- Food and Drug Administration (FDA). (2023). HADLIMA approval notice.
- IQVIA. (2023). The Impact of Biosimilars on the U.S. Market.
- Eurostat. (2022). Biosimilar penetration and pricing analysis in European countries.
- Lazard. (2023). Biosimilar Industry Analysis and Price Trends.
- Centers for Medicare & Medicaid Services (CMS). (2023). Reimbursement policies for biosimilars.
